Type 1 Diabetes

Type 1 Diabetes

Type 1 Diabetes

The OPERA study, conducted by ADSCC, aims to evaluate the safety and efficacy of Extracorporeal Photopheresis (ECP) as a potential treatment for type 1 diabetes mellitus (T1DM).

To be eligible for the study, patients must meet specific criteria, including a confirmed T1DM diagnosis within the first 3 years of onset, use of multiple dose injection therapy, and certain blood parameter requirements. The study is open to individuals aged 18 to 50 who are willing to participate in all tests, visits, and ECP procedures outlined in the informed consent.

The study involves two treatment groups: Group A receives ECP at regular intensity in addition to T1DM standard care, while Group B receives ECP at an accelerated intensity along with standard care. ECP, a procedure with a history of use in various conditions, involves drawing blood, separating white blood cells, combining them with a photoactive drug, and reinfusing them into the patient.

The ECP procedure for each group follows a specific schedule over 24 weeks. Potential risks associated with ECP include common symptoms, bleeding, bruising, pain, infection at the needle sites, citrate-related reactions, allergic reactions, blood-related issues, and rare complications like air embolism or retinal damage.

The primary objective of the study is to assess safety, with a co-primary objective of improving clinical status within 24 weeks post-ECP treatment. Patients will undergo various examinations, including clinical evaluations and specialized laboratory investigations, to assess the effects of the treatment. Additional information about the OPERA Study is available on ClinicalTrials.gov (NCT05413005) or through the provided contact details.

ADSCC’s "SHABABAK" Anti-Aging Program

ADSCC’s “SHABABAK” Anti-Aging Program is a meticulously designed personalized health plan to prevent age-related diseases and enhance overall well-being. Integrating IV therapy, oral supplements, and tailored nutrition, this program focuses on cellular health and vitality.

Our approach goes beyond surface-level concerns by addressing aging at its core, emphasizing disease prevention and promoting internal health. The unique combination of IV therapy, oral supplements, and personalized nutrition supports immune function, enhances cellular repair, and boosts energy levels.

Tailored to individual health needs, this personalized strategy maximizes program benefits. Advanced ingredients like resveratrol, NAD infusion, and NAD booster supplements further contribute to the program’s rejuvenating properties.

The potential benefits of our Anti-Aging Infusion*, designed to enhance your overall well-being, may include:

Increasing energy levels

Combating fatigue

Providing optimal hydration

Boosting immunity

Reducing wrinkles

Slowing aging

Enhancing brain health

Promoting glowing skin

Facilitating stress release

*This product is not intended to diagnose, treat, cure, or prevent any disease.

The program spans 3 months, including a focused 4-week IV infusion phase and a 3-month dietary intervention with orally delivered supplements. While individual outcomes may vary, many participants report increased energy and vitality within the initial weeks, with ongoing improvements observed over time with consistent adherence.

 

Ideal for anyone proactive about health management, the “SHABABAK” Anti-Aging Program at ADSCC is designed to prevent age-related diseases, enhance vitality, and improve overall well-being.

 

If you are interested in taking part in our “SHABABAK” Anti-Aging Program, please contact 800 140 to schedule an appointment with our consultant physician, who will assess your eligibility for the program.

ADSCC’s Executive Screening Program

ADSCC’s Executive Screening Program offers a streamlined approach, consolidating all your essential medical tests within a single week.

Why our Executive Screening Program?

  • To be treated with dignity and respect, consistent with professional standards, for all patients regardless of the manner of payment, race, sex, nationality, religion, culture, disability, or any other factor.
  • To receive care that is considerate, supports patient dignity, is respectful of the patient’s personal values and beliefs, and responds to requests for spiritual and religious observance.
  • To receive healthcare based on clinical need.
  • To receive emergency medical care and treatment easily and promptly.
  • To be referred to a specialist/consultant for special care when there is a clinical need.
  • To receive a detailed explanation of their condition, care, treatment, and aftercare in terms that are free from professional jargon, enabling the patient to fully understand.
  • The patient has the right to access their Medical Record and Medical Information.
  • The right to a second opinion or to have their care transferred to another physician if they are dissatisfied with the care or opinion provided.
  • To privacy during examinations, procedures, clinical care/treatment; they have the right to know who is in attendance and the purpose of those attending them.
  • To protect patients’ possessions from theft or loss.
  • The patient has the right to informed consent for treatment, procedures, and interventions, as per DOH Consent Policy (Reference PPR/HCP/P0003/07).
  • To receive verbal and written information about any proposed treatment and to be informed of available alternatives.
  • To have all clinical and pharmaceutical records kept fully updated and relevant, with information fully documented, and personal details and records kept confidential and protected from loss and misuse.
  • To have the freedom to choose their pharmaceutical care provider.
  • To receive relevant, current, and understandable information concerning their drugs and treatment.
  • To participate in decision-making regarding their drug and treatment choices.
  • To discuss and request information related to their specific drug therapy, possible adverse side effects, and drug interactions.
  • To have drug therapy monitored for safety and efficacy and to make reasonable efforts to detect and prevent drug allergies, adverse reactions, or contraindications.
  • To monitor patient compliance and proper drug use and institute remedial interventions when necessary.
  • To be provided with Arabic/English interpreter services; and all other language barriers will be accommodated based on the availability of translation resources.
  • ADSCC informs patients and families about their rights and responsibilities to refuse or discontinue treatment, withhold resuscitative services, and forgo or withdraw life-sustaining treatments.
  • To have any complaint they make acknowledged, fully investigated, and receive a written response as per the facility’s policy.
  • To receive appropriate protection if they are children, disabled, elderly, or vulnerable. Patients are protected from physical assault, and populations at risk are identified and protected from additional vulnerabilities.
  • To support the patient’s right to assessment and management of pain and receive respectful, compassionate care at the end of life.
  • To be treated with dignity and respect, consistent with professional standards, for all patients regardless of the manner of payment, race, sex, nationality, religion, culture, disability, or any other factor.
  • To receive care that is considerate, supports patient dignity, is respectful of the patient’s personal values and beliefs, and responds to requests for spiritual and religious observance.
  • To receive healthcare based on clinical need.
  • To receive emergency medical care and treatment easily and promptly.
  • To be referred to a specialist/consultant for special care when there is a clinical need.
  • To receive a detailed explanation of their condition, care, treatment, and aftercare in terms that are free from professional jargon, enabling the patient to fully understand.
  • The patient has the right to access their Medical Record and Medical Information.
  • The right to a second opinion or to have their care transferred to another physician if they are dissatisfied with the care or opinion provided.
  • To privacy during examinations, procedures, clinical care/treatment; they have the right to know who is in attendance and the purpose of those attending them.
  • To protect patients’ possessions from theft or loss.
  • The patient has the right to informed consent for treatment, procedures, and interventions, as per DOH Consent Policy (Reference PPR/HCP/P0003/07).
  • To receive verbal and written information about any proposed treatment and to be informed of available alternatives.
  • To have all clinical and pharmaceutical records kept fully updated and relevant, with information fully documented, and personal details and records kept confidential and protected from loss and misuse.
  • To have the freedom to choose their pharmaceutical care provider.
  • To receive relevant, current, and understandable information concerning their drugs and treatment.
  • To participate in decision-making regarding their drug and treatment choices.
  • To discuss and request information related to their specific drug therapy, possible adverse side effects, and drug interactions.
  • To have drug therapy monitored for safety and efficacy and to make reasonable efforts to detect and prevent drug allergies, adverse reactions, or contraindications.
  • To monitor patient compliance and proper drug use and institute remedial interventions when necessary.
  • To be provided with Arabic/English interpreter services; and all other language barriers will be accommodated based on the availability of translation resources.
  • ADSCC informs patients and families about their rights and responsibilities to refuse or discontinue treatment, withhold resuscitative services, and forgo or withdraw life-sustaining treatments.
  • To have any complaint they make acknowledged, fully investigated, and receive a written response as per the facility’s policy.
  • To receive appropriate protection if they are children, disabled, elderly, or vulnerable. Patients are protected from physical assault, and populations at risk are identified and protected from additional vulnerabilities.
  • To support the patient’s right to assessment and management of pain and receive respectful, compassionate care at the end of life.

ADSCC’s Regenerative Packages /General Wellbeing

  • To be treated with dignity and respect, consistent with professional standards, for all patients regardless of the manner of payment, race, sex, nationality, religion, culture, disability, or any other factor.
  • To receive care that is considerate, supports patient dignity, is respectful of the patient’s personal values and beliefs, and responds to requests for spiritual and religious observance.
  • To receive healthcare based on clinical need.
  • To receive emergency medical care and treatment easily and promptly.
  • To be referred to a specialist/consultant for special care when there is a clinical need.
  • To receive a detailed explanation of their condition, care, treatment, and aftercare in terms that are free from professional jargon, enabling the patient to fully understand.
  • The patient has the right to access their Medical Record and Medical Information.
  • The right to a second opinion or to have their care transferred to another physician if they are dissatisfied with the care or opinion provided.
  • To privacy during examinations, procedures, clinical care/treatment; they have the right to know who is in attendance and the purpose of those attending them.
  • To protect patients’ possessions from theft or loss.
  • The patient has the right to informed consent for treatment, procedures, and interventions, as per DOH Consent Policy (Reference PPR/HCP/P0003/07).
  • To receive verbal and written information about any proposed treatment and to be informed of available alternatives.
  • To have all clinical and pharmaceutical records kept fully updated and relevant, with information fully documented, and personal details and records kept confidential and protected from loss and misuse.
  • To have the freedom to choose their pharmaceutical care provider.
  • To receive relevant, current, and understandable information concerning their drugs and treatment.
  • To participate in decision-making regarding their drug and treatment choices.
  • To discuss and request information related to their specific drug therapy, possible adverse side effects, and drug interactions.
  • To have drug therapy monitored for safety and efficacy and to make reasonable efforts to detect and prevent drug allergies, adverse reactions, or contraindications.
  • To monitor patient compliance and proper drug use and institute remedial interventions when necessary.
  • To be provided with Arabic/English interpreter services; and all other language barriers will be accommodated based on the availability of translation resources.
  • ADSCC informs patients and families about their rights and responsibilities to refuse or discontinue treatment, withhold resuscitative services, and forgo or withdraw life-sustaining treatments.
  • To have any complaint they make acknowledged, fully investigated, and receive a written response as per the facility’s policy.
  • To receive appropriate protection if they are children, disabled, elderly, or vulnerable. Patients are protected from physical assault, and populations at risk are identified and protected from additional vulnerabilities.
  • To support the patient’s right to assessment and management of pain and receive respectful, compassionate care at the end of life.
  • To be treated with dignity and respect, consistent with professional standards, for all patients regardless of the manner of payment, race, sex, nationality, religion, culture, disability, or any other factor.
  • To receive care that is considerate, supports patient dignity, is respectful of the patient’s personal values and beliefs, and responds to requests for spiritual and religious observance.
  • To receive healthcare based on clinical need.
  • To receive emergency medical care and treatment easily and promptly.
  • To be referred to a specialist/consultant for special care when there is a clinical need.
  • To receive a detailed explanation of their condition, care, treatment, and aftercare in terms that are free from professional jargon, enabling the patient to fully understand.
  • The patient has the right to access their Medical Record and Medical Information.
  • The right to a second opinion or to have their care transferred to another physician if they are dissatisfied with the care or opinion provided.
  • To privacy during examinations, procedures, clinical care/treatment; they have the right to know who is in attendance and the purpose of those attending them.
  • To protect patients’ possessions from theft or loss.
  • The patient has the right to informed consent for treatment, procedures, and interventions, as per DOH Consent Policy (Reference PPR/HCP/P0003/07).
  • To receive verbal and written information about any proposed treatment and to be informed of available alternatives.
  • To have all clinical and pharmaceutical records kept fully updated and relevant, with information fully documented, and personal details and records kept confidential and protected from loss and misuse.
  • To have the freedom to choose their pharmaceutical care provider.
  • To receive relevant, current, and understandable information concerning their drugs and treatment.
  • To participate in decision-making regarding their drug and treatment choices.
  • To discuss and request information related to their specific drug therapy, possible adverse side effects, and drug interactions.
  • To have drug therapy monitored for safety and efficacy and to make reasonable efforts to detect and prevent drug allergies, adverse reactions, or contraindications.
  • To monitor patient compliance and proper drug use and institute remedial interventions when necessary.
  • To be provided with Arabic/English interpreter services; and all other language barriers will be accommodated based on the availability of translation resources.
  • ADSCC informs patients and families about their rights and responsibilities to refuse or discontinue treatment, withhold resuscitative services, and forgo or withdraw life-sustaining treatments.
  • To have any complaint they make acknowledged, fully investigated, and receive a written response as per the facility’s policy.
  • To receive appropriate protection if they are children, disabled, elderly, or vulnerable. Patients are protected from physical assault, and populations at risk are identified and protected from additional vulnerabilities.
  • To support the patient’s right to assessment and management of pain and receive respectful, compassionate care at the end of life.